Competitive and Market Trend Analysis of Late Stage Chronic Kidney Disease Drugs Industry Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Late Stage Chronic Kidney Disease Drugs Market Through 2029?
The market size of drugs for late-stage chronic kidney disease has seen a fast-paced escalation in the recent past. The market is projected to rise from $7.08 billion in 2024 to $7.86 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.1%. The historical growth is a consequence of multiple factors such as enhanced diagnostic capabilities, increasing number of aged individuals, spikes in diabetes and hypertension cases, more awareness about kidney ailments, and extensive expansion in pharmaceutical research and development.
In the coming years, the market size for drugs treating late-stage chronic kidney disease is anticipated to witness swift expansion. By 2029, the market is projected to reach $12.11 billion, with a compound annual growth rate (CAGR) of 11.4%. This predicted expansion during the forecasted period can be linked to factors such as increased spending on healthcare, adoption of precise medical approaches, a growing focus on regenerative medicine, heightened attention to patient-oriented care, and worldwide efforts to raise awareness about kidney diseases. The forecast period will also see a rise in trends such as the growth of regenerative medicine therapies, increased uptake of telemedicine services for CKD management, the development of therapy combinations, more emphasis on early intervention strategies, and a growing interest in diagnostics based on biomarkers.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp
What Market Forces Are Driving The Late Stage Chronic Kidney Disease Drugs Sector In 2025 And Beyond?
The escalating incidence of chronic kidney diseases is anticipated to fuel the expansion of the late-stage chronic kidney disease drug market. Chronic kidney diseases encompass a variety of conditions that impact the functioning and structure of the kidneys. Drugs for late-stage chronic kidney disease are employed to manage patients’ blood pressure, reduce protein loss, halt kidney damage progression, manage symptoms, and prevent outcomes. For instance, the Centers for Disease Control and Prevention (CDC), a public health agency based in the US, estimated in May 2024 that about 14% of American adults, equating to roughly 35.5 million people, are presumed to be suffering from chronic kidney diseases. Hence, the widespread chronic kidney disease is spurring the growth of the late-stage chronic kidney disease drug market.
How Is The Global Late Stage Chronic Kidney Disease Drugs Market Categorized By Segments?
The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
What Long-Term Trends Are Likely To Affect The Late Stage Chronic Kidney Disease Drugs Market?
The introduction of new and innovative products into the market is a growing trend in the late-stage chronic kidney disease drug industry. Major industry players are creating new drug products to maintain their market standing. An example of this occurred in February 2022 when Bayer, a pharmaceutical and biotech firm based in Germany, unveiled Kerendia (finerenone) in India. This first-of-its-kind non-steroidal, selective mineralocorticoid receptor antagonist is recommended for patients suffering from type two diabetes and chronic renal disease. Finerenone operates by inhibiting the overactivation of the mineralocorticoid receptor (MR), believed to contribute to the onset of chronic kidney disease (CKD) and cardiovascular damage.
Which Firms Are Considered Leaders In The Late Stage Chronic Kidney Disease Drugs Market Space?
Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc
Get The Full Report Here:
What Role Do Regional Policies And Investments Play In Late Stage Chronic Kidney Disease Drugs Market Expansion?
North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12196&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
